Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Lectins are carbohydrate-binding proteins, whose biological effects are exerted via binding to glycoconjugates expressed on the surface of cells. Exposure to lectins can lead not only to a change in the structure and properties of cells but also to their death. Here, we studied the biological activity of lectins from the mussels Crenomytilus graynus (CGL) and Mytilus trossulus (MTL) and showed that these proteins can affect the proliferation of human lymphoma cells. Both lectins suppressed the formation of colonies as well as cell cycle progression. The mechanism of action of these lectins was not mediated by reactive oxygen species but included damaging of mitochondria, inhibition of key cell cycle points, and activation of MAPK signaling pathway in tumor cells. Computer modeling suggested that various effects of CGL and MTL on lymphoma cells may be due to the difference in the energy of binding of these lectins to carbohydrate ligands on the cell surface. Thus, molecular recognition of residues of terminal carbohydrates on the surface of tumor cells is a key factor in the manifestation of the biological action of lectins.

Download full-text PDF

Source
http://dx.doi.org/10.1002/iub.2909DOI Listing

Publication Analysis

Top Keywords

lymphoma cells
12
lectins
8
cgl mtl
8
cells lectins
8
cell cycle
8
action lectins
8
tumor cells
8
cells
7
lectins cgl
4
mtl representatives
4

Similar Publications

Injections have been linked to feline sarcomas (feline injection-site sarcoma; FISS) and cutaneous lymphomas (cutaneous lymphoma at injection site; CLIS). Both tumors often exhibit lymphoplasmacytic inflammation ascribed to injected immunogenic material. CLIS is hypothesized to emerge from transformation and clonal expansion of lymphoid cells following persistent immune stimulation with feline leukemia virus (FeLV) reactivation and transformation.

View Article and Find Full Text PDF

Mathematical model suggests current CAR-macrophage dosage is efficient to low pre-infusion tumour burden but refractory to high tumour burden.

J Theor Biol

September 2025

Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China. Electronic address:

Chimeric antigen receptor (CAR)-macrophage therapy is a promising approach for tumour treatment due to antigen-specific phagocytosis and tumour clearance. However, the precise impact of tumour burden, dose and dosing regimens on therapeutic outcomes remains poorly understood. We developed ordinary differential equation (ODE) mathematical modelling and utilised parameter inference to analyse in vitro FACS-based phagocytosis assay data testing CD19-positive Raji tumour cell against CAR-macrophage, and revealed that phagocytosing efficiency of CAR-macrophage increases but saturates as both Raji cell and CAR-macrophage concentrations increase.

View Article and Find Full Text PDF

In a subset of patients with systemic mastocytosis (SM), an associated hematologic neoplasm (AHN) is identified. Most AHN are myeloid neoplasms, whereas lymphoid neoplasms are uncommon. We report on a 70-year-old female patient with bone marrow mastocytosis (BMM) associated with primary cutaneous follicle center lymphoma (PCFCL).

View Article and Find Full Text PDF

Targeted delivery and pro-apoptotic efficacy of an Epstein-Barr virus nuclear antigen 1-specific affibody in EBV-infected cells in vitro.

Int J Biol Macromol

September 2025

Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. Electronic address:

Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) sustains viral latency and drives oncogenesis in EBV-driven malignancies such as nasopharyngeal carcinoma and lymphomas. The dimerization of EBNA1 acts as an indispensable molecular switch governing EBV latency and oncogenesis. Disruption of EBNA1 dimerization is a promising strategy, but existing small-molecule inhibitors lack sufficient specificity.

View Article and Find Full Text PDF

T-cell acute lymphoblastic leukemia (T‑ALL) is an aggressive hematological malignancy. The poor prognosis of T‑ALL is closely associated with extensive leukemic infiltration into critical organs. Therefore, the mechanism underlying T‑ALL infiltration is worth investigating.

View Article and Find Full Text PDF